Next earnings date: 10 Sep 2025

NKGen Biotech, Inc. Common Stock – NASDAQ:NKGN

Add to watchlist

$0.14

-0.57

-80.37%

Market open

Closed in about 4 hours

-25.73%

month

-25.73%

quarter

-78.52%

year

Market Cap	23.26M
Enterprise value	N/A

P/E	N/A
EV/Sales	N/A
EV/EBITDA	N/A
Price/Sales	N/A
Price/Book	N/A
PEG ratio	N/A
EPS	-4.38

Revenue	N/A
EBITDA	-26.00M
Income	-73.99M
Revenue Q/Q	N/A
Revenue Y/Y	-100%

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

NKGen Biotech, Inc. Common Stock (NASDAQ:NKGN): Profit margin
Jun 2023	0	-1.83M
Sep 2023	0	-33.17M
Dec 2023	0	-33.60M
Mar 2024	0	-5.38M

NKGen Biotech, Inc. Common Stock (NASDAQ:NKGN): Debt to assets
Jun 2023	63605533	9.34M	14.7%
Sep 2023	25198000	65.83M	261.27%
Dec 2023	34773000	75.17M	216.18%
Mar 2024	26705000	71.37M	267.26%

NKGen Biotech, Inc. Common Stock (NASDAQ:NKGN): Cash Flow
Jun 2023	-552.05K	113.26M	-112.87M
Sep 2023	-13.94M	-113.37M	136.83M
Dec 2023	-6.93M	-18K	-1.80M
Mar 2024	-4.03M	35K	4.00M

NKGen Biotech, Inc. Common Stock alternative data

NKGen Biotech, Inc. Common Stock
Employees

NKGen Biotech, Inc. Common Stock (NASDAQ:NKGN): Employee count
Mar 2024	65
Apr 2024	65
Jun 2024	63
Jul 2024	63

NKGen Biotech, Inc. Common Stock
Latest News

Monday, 2 December 2024
16:05	NKGen Biotech Selected as Stalking Horse Bidder for NKMax	globenewswire.com
Tuesday, 26 November 2024
16:15	NKGen Biotech Receives Notifications From Nasdaq Related to Delayed Quarterly Report and Decision of the Nasdaq Hearings Panel	globenewswire.com
Tuesday, 29 October 2024
08:05	NKGen Biotech Presents Phase 1/2a Troculeucel Data in Alzheimer's Disease at the 17th Annual Clinical Trials on Alzheimer's Disease (CTAD) Conference	globenewswire.com
Tuesday, 15 October 2024
08:05	NKGen Biotech Announces Upcoming Presentation at the 16th World Stroke Congress (WSC 2024)	globenewswire.com
Tuesday, 8 October 2024
08:05	NKGen Biotech Announces Poster Presentations at the 17th Annual Clinical Trials on Alzheimer's Disease (CTAD) Conference	globenewswire.com
Thursday, 12 September 2024
08:05	NKGen Biotech's Positive Phase 1 Clinical Data in Moderate Alzheimer's Disease Advances Troculeucel into Phase 2 with First Patient Dosed in Phase 1/2a Trial	globenewswire.com
Tuesday, 3 September 2024
08:05	NKGen Biotech to Present at the H.C. Wainwright 26th Annual Global Investment Conference	globenewswire.com
Thursday, 22 August 2024
16:40	NKGen Biotech Receives Notification From Nasdaq Related to Delayed Quarterly Report	globenewswire.com
Tuesday, 30 July 2024
08:05	NKGen Biotech Presents New Positive SNK01 Biomarker Data at the 2024 Alzheimer's Association International Conference	globenewswire.com
Thursday, 18 July 2024
11:30	Why Is NKGen Biotech (NKGN) Stock Up 18% Today?	investorplace.com
08:05	NKGen Biotech to Present New Positive SNK01 Clinical Trial Biomarker Data at the 2024 Alzheimer's Association International Conference	globenewswire.com
Monday, 15 July 2024
08:05	NKGen Biotech Appoints Dr. Marco Gottardis to its Board of Directors	globenewswire.com
Wednesday, 12 June 2024
13:05	NKGen Biotech Presents Updated Phase 1 Data on SNK02 Allogeneic NK Cell Therapy for Solid Tumors at the 6th Annual Allogeneic Cell Therapies Summit 2024	globenewswire.com
Monday, 3 June 2024
08:05	NKGen Biotech To Present Updated Phase 1 Data on SNK02 Allogeneic NK Cell Therapy in Solid Tumors at the 6th Annual Allogeneic Cell Therapies Summit 2024	globenewswire.com
Thursday, 23 May 2024
17:05	NKGen Biotech Publishes Phase 1 Interim Analysis Results of SNK02 Allogeneic NK Cell Therapy in Advanced Solid Tumors at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting	globenewswire.com
Monday, 20 May 2024
11:41	NKGN Stock Alert: The Alzheimer's News That Has NKGen Biotech Soaring Today	investorplace.com
08:05	NKGen Biotech's SNK01 NK Cell Therapy Cleared to Start Phase 2 Clinical Trial in Alzheimer's Disease	globenewswire.com
Thursday, 16 May 2024
08:05	NKGen Biotech Announces Upcoming Presentation on Autologous NK Cell Therapy at the 5th International Cell & Gene Therapy China Summit & Exhibition	globenewswire.com
Monday, 29 April 2024
08:00	NKGen Biotech Announces FDA Clearance of Investigational New Drug (IND) Application for SNK01 NK Cell Therapy in Parkinson's Disease	globenewswire.com
Thursday, 25 April 2024
16:05	NKGen Biotech Presents Updated NK Cell Therapy Data for Neurodegenerative Disease at the 12th Annual Alzheimer's & Parkinson's Drug Development Summit	globenewswire.com
Wednesday, 24 April 2024
16:45	NKGen Biotech Announces Upcoming Publication at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting	globenewswire.com
Thursday, 18 April 2024
16:05	NKGen Biotech Announces Upcoming Presentation on SNK01 NK Cell Therapy in Neurodegenerative Disease at the 12th Annual Alzheimer's & Parkinson's Drug Development Summit	globenewswire.com
Thursday, 11 April 2024
08:05	NKGen Biotech Secures Additional Financing of $5 Million to Continue Advancing Its Clinical Programs	globenewswire.com
Monday, 25 March 2024
16:05	NKGen Biotech Presents Additional Phase 1 Clinical Trial Data in Alzheimer's Disease at the Tau2024 Global Conference	globenewswire.com
Wednesday, 6 March 2024
07:52	Why Is NKGen Biotech (NKGN) Stock Up 62% Today?	InvestorPlace
Friday, 27 October 2023
07:50	Why Is NKGen Biotech (NKGN) Stock Up 18% Today?	InvestorPlace

Frequently Asked Questions (FAQ)

What's the price of NKGen Biotech, Inc. Common Stock stock today?

One share of NKGen Biotech, Inc. Common Stock stock can currently be purchased for approximately $0.14.
When is NKGen Biotech, Inc. Common Stock's next earnings date?

NKGen Biotech, Inc. Common Stock is estimated to report earnings on Wednesday, 10 Sep 2025.
Does NKGen Biotech, Inc. Common Stock pay dividends?

No, NKGen Biotech, Inc. Common Stock does not pay dividends.
How much money does NKGen Biotech, Inc. Common Stock make?

NKGen Biotech, Inc. Common Stock has a market capitalization of 23.26M.
What is NKGen Biotech, Inc. Common Stock's stock symbol?

NKGen Biotech, Inc. Common Stock is traded on the NASDAQ under the ticker symbol "NKGN".
What is NKGen Biotech, Inc. Common Stock's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of NKGen Biotech, Inc. Common Stock?

Shares of NKGen Biotech, Inc. Common Stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
How many employees does NKGen Biotech, Inc. Common Stock have?

As Jul 2024, NKGen Biotech, Inc. Common Stock employs 63 workers, which is 3% less then previous quarter.
When NKGen Biotech, Inc. Common Stock went public?

NKGen Biotech, Inc. Common Stock is publicly traded company for just a year since IPO on 2 Oct 2023.
What is NKGen Biotech, Inc. Common Stock's official website?

The official website for NKGen Biotech, Inc. Common Stock is grafacq.com.
Where are NKGen Biotech, Inc. Common Stock's headquarters?

NKGen Biotech, Inc. Common Stock is headquartered at 1790 Hughes Landing Boulevard, The Woodlands, TX.
How can i contact NKGen Biotech, Inc. Common Stock?

NKGen Biotech, Inc. Common Stock's mailing address is 1790 Hughes Landing Boulevard, The Woodlands, TX and company can be reached via phone at +34 64420819.

NKGen Biotech, Inc. Common Stock

grafacq.com

Exchange:

NASDAQ

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

Graf Acquisition Corp. IV does not have significant operations. It focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or other business combination with one or more businesses. Graf Acquisition Corp. IV was incorporated in 2021 and is based in The Woodlands, Texas.

+34 64420819

1790 Hughes Landing Boulevard
The Woodlands, TX 77380

CIK: 0001845459
ISIN: US65488A1016
: